<div><p><b>Background: </b>Studies on incident liver and cardiovascular outcomes in lean (body mass index: BMI &lt;25 kg/m², or &lt;23 kg/m² for Asians) vs. non-lean individuals with metabolic dysfunction-associated steatohepatitis (MASH) have reported mixed results. We aimed to compare incident clinical outcomes and mortality between lean and non-lean individuals with compensated MASH cirrhosis in a large national cohort.</p>

<div><p><b>Background: </b>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease in the US. Notably, disease prevalence differs greatly by race/ethnicity, with the highest prevalence in those of Hispanic and Asian ancestry, and the lowest prevalence in those of African ancestry. To date, studies have identified common variants associated with MASLD in predominantly European or American populations.

<div><p><b>Background: </b>Telemedicine removes geographic and temporal obstacles to healthcare access. Few randomized trials have evaluated telemedicine effectiveness for underserved populations. We compared sustained virological response (SVR12) rates for hepatitis C virus (HCV) infection among persons with opioid use disorder through facilitated telemedicine (FTM) versus offsite liver specialist referral (usual care or UC).</p>

<div><p><b>Background: </b>Retatrutide (RETA; LY3437943) is a novel triple agonist of the GIP, GLP-1 and glucagon receptors under investigation for obesity treatment. A 48-week phase 2 obesity study demonstrated weight loss of −22.8% and −24.2% with RETA 8 and 12 mg. We report effects of RETA on liver fat (LF) and correlations with metabolic measures in subjects with MASLD included in this trial.</p>

<div><p><b>Background: </b>HBV and HIV are both major global health concerns as HBV infects 296 million people while HIV infects 38 million individuals worldwide.HIV/HBV co-infection is common due to similar routes of transmission, with an estimated 10% of HIV-infected individuals also infected with HBV. HIV/HBV co-infected individuals progress to chronic HBV infection more frequently and exhibit reduced HBV-specific T cell responses, with a higher probability of extensive liver fibrosis and hepatocellular carcinomas.

<div><p><strong>Background</strong>: Quality of life and symptom management are important for patients with chronic liver disease (CLD), which can precede cirrhosis development. CLD patients with/without cirrhosis have mood disorders which affect cognition. Cognitive impairment is testing using simple (Animal naming, ANT) or more complicated [Stroop and Psychometric hepatic encephalopathy score (PHES)] but their impact on QOL across the spectrum of CLD is unclear.

<div><p><b>Background: </b>ECM1 depletion results in excessive latent TGF-β1 activation and lethal liver fibrosis in mice. In patients suffering from chronic liver diseases, ECM1 expression gradually decreases with increasing severity of fibrosis. We investigated the underlying mechanisms of how ECM1 contributes to tissue homeostasis in healthy livers and what changes occur during CLD progression.</p>

<div><p><b>Background:</p> </b><div><p>

<div><p><b>Background: </b>We have previously reported that vitamin K dosing augments the anticancer effects of sorafenib by suppressing levels of des-γ-carboxy prothrombin (DCP), a known tumor growth and angiogenesis factor produced in HCC under sorafenib-induced ischemia. Herein, we aimed to establish whether vitamin K dosing could afford a similar anticancer effect when combined with transarterial chemoembolization (TACE), known to induce ischemic tumor necrosis in HCC.</p>

<div><p><b>Background: </b>While obesity is a risk factor for NAFLD, patients across the BMI spectrum are affected by the disease, creating a need for reliable non-invasive tests (NITs) with performances that are not affected by BMI. While most of standard NITs are designed to detect advanced fibrosis, NIS2+™, an optimization of the blood-based NIS4® technology, is specifically designed to detect at-risk NASH (<span>NAS≥4; F≥2</span>).